Published in final edited form as:

Chem Commun (Camb). 2015 June 28; 51(51): 10310–10313. doi:10.1039/c5cc03746h.

Efficient chemoenzymatic synthesis of novel galacto-*N*-biose derivatives and their sialylated forms

Lei Li^{a,b}, Yonghui Liu^b, Tiehai Li^a, Wenjun Wang^b, Zaikuan Yu^a, Cheng Ma^a, Jingyao Qu^a, Wei Zhao^b, Xi Chen^c, and Peng G Wang^a

Lei Li: lli22@gsu.edu; Peng G Wang: pwang11@gsu.edu

^aDepartment of Chemistry and Center for Diagnostics & Therapeutics, Georgia State University, Atlanta, GA 30303, USA

^bState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin 300071, PR China

^cDepartment of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA

Abstract

Galacto-*N*-biose (GNB) derivatives were efficiently synthesized from galactose derivatives via a one-pot two-enzyme system containing two promiscuous enzymes from *Bifidobacterium infantis*: a galactokinase (BiGalK) and a D-galactosyl- β 1–3-*N*-acetyl-D-hexosamine phosphorylase (BiGalHexNAcP). Mono-sialyl and di-sialyl galacto-*N*-biose derivatives were then prepared using a one-pot two-enzyme system containing a CMP-sialic acid synthetase and an α 2–3-sialyltransferase or an α 2–6-sialyltransferase.

Graphical abstract

Disaccharide galacto-*N*-biose (GNB, Gal β 1–3GalNAc) is a common glycan structure in nature. GNB with an α -configuration at the reducing end linked to the serine or threonine residue in glycoproteins (Gal β 1–3GalNAc α Ser/Thr) is named T-antigen and is one of the most common tumor-associated carbohydrate antigens (TATCs) found overexpressed on human carcinoma cells, including those of lung cancer, prostate cancer, breast cancer, etc.¹

Correspondence to: Lei Li, lli22@gsu.edu; Peng G Wang, pwang11@gsu.edu.

[†]Electronic Supplementary Information (ESI) available: Experimental details for substrate specificity study and enzymatic synthesis, NMR and HRMS data and spectra. See DOI: 10.1039/c000000x/

T-antigen is also a key component of core 1, core 2, and their extended forms of mucin-type O-GalNAc glycoproteins.² In addition, GNB with an α -configuration at the reducing end is part of type 3 human blood group antigens³ (Fig. 1). On the other hand, GNB with a β -configuration at the reducing end (Gal β 1–3GalNAc β) is an essential part of globo-series (e.g. Globo-H, Gb5, sialyl Gb5) and ganglio-series (e.g. GA1, GM1, GD1, GT1, GP1, GQ1, etc) glycosphingolipids,⁴ and type 4 human blood group antigens³. Furthermore, GNB and its derivatives [e. g. GalA β 1–3GalNAc with the galactose (Gal) residue at the non-reducing end in GNB being replaced by galacturonic acid (GalA)] have been found in cell surface oligosaccharides or polysaccharides of various bacteria⁵ (Fig. 1). Sialyl GNB (Neu5Ac α 2–3Gal β 1–3GalNAc) and di-sialyl GNB [Neu5Ac α 2–3Gal β 1–3(Neu5Ac α 2–6)GalNAc], which are common terminal glycan structures found in gangliosides (Fig. 1), play significant roles in intermolecular interactions. For example, the sialyl GNB-terminated ganglioside GM1b serves as a receptor for H3N2 influenza virus during infection.⁶ It is also closely related to Guillain-Barré syndrome.⁷ On the other hand, the terminal di-sialyl GNB component of gangliosides GD1 α , GT1 α and GQ1 α is the minimal binding epitope of myelin-associated glycoprotein (MAG) ligands,⁸ and is considered as a leading target for developing MAG inhibitors to enhance regeneration of central nervous system axons after injury in adult mammals.⁹

Given their significances, both chemical¹⁰ and enzymatic strategies¹¹ were developed for the synthesis of these glycans. Previously, we cloned a novel D-galactosyl- β 1–3-*N*-acetyl-D-hexosamine phosphorylase from *Bifidobacterium infantis* (BiGalHexNAcP), and developed a highly efficient one-pot two-enzyme system for rapid preparation of GNB and lacto-*N*-biose (LNB, Gal β 1–3GlcNAc) as well as their derivatives.¹² This system includes a galactokinase from *E. coli* (EcGalK) which catalyzes the formation of galactose-1-phosphate (Gal-1-P) from Gal, and BiGalHexNAcP that catalyzes the transfer of Gal from Gal-1-P to various acceptors including *N*-acetylgalactosamine (GalNAc), *N*-acetylglucosamine (GlcNAc) and their derivatives. It is worth nothing that this system is almost equally efficient in preparing GNB/LNB derivatives with both α - and β -configurations at the reducing end.¹² Comparing to glycosyltransferase (GT)-catalyzed reactions, such a system not only avoids in situ re-generation of valuable sugar nucleotides (e.g. UDP-Gal), but also simplifies product purification since the reaction mixture excludes UDP/UTP. Other than the observed acceptor substrate specificity observed,¹² a later success in utilizing this system to prepare GNB derivatives containing 6-deoxy-6-fluoro-Gal (Gal6F)¹³ indicates the promiscuity of BiGalHexNAcP towards sugar-1-phosphate donors. Nevertheless, the donor specificity of BiGalHexNAcP has not been studied in detail. Various GNB, sialyl GNB, and di-sialyl GNB derivatives are still in great demand as glycan probes or precursors for biological studies. In this study, we described an efficient one-pot two-enzyme system that combines BiGalHexNAcP and a promiscuous galactokinase from *B. infantis* (BiGalK) for the production of GNB derivatives containing Gal derivatives, including those with 2-deoxy-Gal, 6-deoxy-Gal, 6-azido-Gal, 6-fluoro-6-deoxy-Gal, and GalA. The obtained compounds were then used for acceptor substrate specificity studies of two bacterial sialyltransferases and for the preparative synthesis of novel sialyl GNB and di-sialyl GNB derivatives.

As shown in Scheme 1, the one-pot two-enzyme system contains: 1) BiGalK, which catalyzes the formation of Gal-1-P and derivatives from monosaccharides in the presence of

ATP; 2) BiGalHexNAcP, which transfers monosaccharides onto GalNAc to form diverse GNB derivatives. EcGalK was originally used in the system to generate Gal-1-P. However, it was found that at the optimal reaction pH of BiGalHexNAcP (5.0–6.5), EcGalK showed dramatically reduced phosphorylation activity towards Gal.¹³ Thus, a two-step process was used previously in the one-pot two-enzyme synthesis of fluorinated T-antigens, where reaction pH was adjusted to meet the optimal pH of each enzyme in corresponding steps.¹³ BiGalK¹⁴ and another galactokinase from *Meiothermus taiwanensis* (MtGalK)¹⁵ are two recently discovered galactokinases with extremely high activity towards Gal. They also exhibit relaxed substrate specificity towards different Gal derivatives, for example, BiGalK can accept 2-deoxy-Gal (Gal2deoxy, **2**), galactosamine (GalNH₂, **3**), 6-deoxy-Gal (**7**), and galacturonic acid (GalA, **8**)¹⁴, and MtGalK can accept GalNH₂ (**2**), 2-deoxy-2-azido-Gal (GalN₃, **4**) and *N*-acetylglycosamine (GalNAc).¹⁵ Given that the yield of BiGalK (over 80 mg/L culture)¹⁴ is 4 times higher than that of MtGalK (16 mg/L culture),¹⁵ BiGalK was chosen in this study for the synthesis of GNB and derivatives. To further study the substrate specificity of BiGalK, and determine whether it can be used in the one-pot two-enzyme system, the phosphorylation activity of BiGalK towards a panel of C2 and C6 modified Gal were tested at pH 6.5. As shown in Table S1 and Figure S1, except for 2-deoxy-2-azido-Gal (GalN₃, **4**), 6-deoxy-Gal (Gal6deoxy, **7**) and GalA (**8**), which had moderate yield (63%, 60% and 53% respectively), BiGalK could efficiently phosphorylate Gal (**1**) and all other derivatives (**2**, **3**, **5**, **6**, **9**) at pH 6.5 with yields of 76% to 96%. Even though specific activities of BiGalK towards C6 modified Gal are much lower than towards Gal (e.g. 0.0906 $\mu\text{mol min}^{-1} \text{mg}^{-1}$ towards GalA), it is still efficient enough to prepare corresponding Gal-1-P derivatives on a preparative scales.¹⁶ These results indicate that BiGalK is promiscuous towards C2 or C6 modified Gal in mild acidic (pH 6.5) conditions, which is suitable for the proposed one-pot two-enzyme system (Scheme 1). Preparative scale synthesis and purification of corresponding Gal-1-P derivatives were carried out, and the structures were confirmed by MS and NMR analysis (Supporting Information).

The synthesis of GNB and derivatives was carried out using the one-pot two-enzyme system shown in Scheme 1. Excess amounts of BiGalK were added to achieve high phosphorylation efficiency towards each monosaccharide (see detailed methods and compounds characterization in Supporting Information). As listed in Table 1, the system was quite efficient in synthesizing GNB (**12**, 95%), 2-deoxy-Gal β 1–3GalNAc (**13**, 80%), 6-deoxy-Gal β 1–3GalNAc (**18**, 87%), GalA β 1–3GalNAc (**19**, 84%), and Gal6N₃ β 1–3GalNAc (**20**, 76%) from corresponding Gal or derivatives (**1**, **2**, **7**, **8**, **9**). In contrast, the synthesis of GalNH₂ β 1–3GalNAc (**14**), GalN₃ β 1–3GalNAc (**15**), Tal β 1–3GalNAc (**17**) was not successful using the one-pot two-enzyme system. Most interestingly, GalF β 1–3GalNAc (**16**) and GalF β 1–3GlcNAc (**45**, Table S2) were able to be synthesized using either GalNAc or GlcNAc as acceptors, even though with relatively low yields (28%, 18.3 mg; 26%, 17.0 mg respectively). Preparation of such compounds using GTs catalyzed reactions was proven to be impossible, since UDP-GalF, the required donor, is usually an inhibitor of GTs.¹⁷ These 2-deoxy-2-fluoro modified glycans may find great application as inhibitors or probes in biological studies. Taken together with the high-yield synthesis of Gal6F β 1–3GalNAc (**21**, 80%) reported previously,¹³ these results suggest that in donor substrate recognition, BiGalHexNAcP is quite relaxed towards C6 modifications of Gal, but relatively strict

towards C2 modifications. Similar results were obtained when using GlcNAc as an acceptor in the one-pot two-enzyme system for the synthesis of LNB and derivatives (Table S2).

Pasteurella multocida α 2–3-sialyltransferase 1 (PmST1) and its mutants were found to be extremely useful in preparing bioactive α 2–3-sialosides and derivatives.¹⁸ The donor substrate specificity of the enzyme has been extensively investigated, whereas the acceptor substrate specificity studies have been limited. Only those with a non-modified Gal (either free or linked to other glycans) or Gal6F (Gal6F β 1–3GalNAc)^{17b} at the non-reducing end have been tested. The access to various GNB derivatives with modifications on the Gal residue allowed us to further study the acceptor specificity of PmST1, and to synthesize novel α 2–3-sialosides. As shown in Scheme 2, a one-pot two-enzyme system was used for this purpose. The sugar donor, CMP-Neu5Ac was first generated from *N*-acetylneuraminic acid (Neu5Ac) and cytidine 5'-triphosphate (CTP) by *Neisseria meningitidis* CMP-Sia synthetase (NmCSS)¹⁹ in presence of Mg²⁺. Secondly, the Neu5Ac on CMP-Neu5Ac was transferred onto the Gal via an α 2–3-linkage to form sialyl GNB.

As listed in Table 2, the system was highly efficient in sialylating all GNB derivatives except for GalA β 1–3GalNAc (**19**) (see detailed methods and compounds characterization in Supporting Information). These results imply that PmST1 could tolerate modifications at the C2 of Gal (Compounds **13**, **16**), and most importantly, it has good tolerance towards modifications at the C6 of Gal including a deoxy substituent (Compound **18**) or an azido substituent (Compound **20**). However, PmST1 could hardly accept **19** (16% yield), which may be caused by the negative charge of the C6 carboxyl group in GalA.

Given the significant roles that the terminal di-sialyl GNB play in ganglioside-MAG interaction, it is of great synthetic interest. Previously, *Photobacterium damsela* α 2–6-sialyltransferase (Pd2,6ST)²⁰ was used to generate di-sialyl GNB from sialyl GNB, however, a glycan mixture was obtained due to non-specific sialylation of either the Gal or the GlcNAc residue of GNB by Pd2,6ST.²¹ A “substrate engineering” strategy was then developed to overcome the problem,²¹ including: 1) chemical formation of 1,4-lactone between the C1'' carboxyl group of Neu5Ac and the C4' hydroxyl group of Gal on sialyl GNB to prevent α 2–6-sialylation of Gal, followed by 2) Pd2,6ST-catalyzed α 2–6-sialylation of GalNAc and 3) saponification to yield di-sialyl GNB.

We propose that removing or replacing the C6 hydroxyl group of the Gal residue would prevent non-specific sialylation at the Gal, thus provide a direct approach for the formation of useful di-sialyl GNB derivatives. The access of three sialyl GNB derivatives (**25**, **26**, **27**) with modifications at the C6 of the Gal allows us to test this approach. As shown in Scheme 3, the di-sialyl GNB derivatives were synthesized using a one-pot two-enzyme system, which contains 1) NmCSS for catalyzing the in situ generation of CMP-Neu5Ac, and 2) Pd2,6ST for catalyzing the α 2–6-sialylation of the internal GalNAc residue of sialyl GNB derivatives. As expected, three corresponding di-sialyl GNB derivatives were successfully synthesized with moderate (**29**, 57%) to high yields (**28**, 81%; **30**, 75%) (Table 3), and no by-products were found by either mass spectrometry (MS) or thin-layer chromatography (TLC) analysis. These results indicate that Pd2,6ST can tolerate sialyl-GNB with modifications at the C6 of Gal, and it is a practical and reliable approach to synthesize di-

sialyl GNB with appropriated C6 modifications of the Gal residue. Such an approach not only provided well-controlled synthesis of di-sialyl GNB mimicking natural gangliosides, but also introduced functional groups (e.g. -N₃) potentially useful for molecular probing. Furthermore, compare with the previously reported “substrate engineering” strategy,²¹ this approach excluded chemical protection/deprotection steps.

In summary, taking advantages of the acceptor substrate promiscuity of BiGalK and donor substrate promiscuity of BiGalHexNAcP, various novel GNB and LNB derivatives were synthesized using an efficient one-pot two-enzyme system. These compounds were used for acceptor substrate specificity study of PmST1 and efficient synthesis of sialyl GNB derivatives. Finally, well-controlled synthesis of di-sialyl GNB was achieved by selectively blocking one of the C6-glycosylation sites on Gal/GalNAc in the substrates. The compounds synthesized in this study are valuable probes for elucidating the biological roles of GNB, sialyl and di-sialyl GNB-containing glycans.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by National Natural Science Foundation of China grant 31100587 (to L. Li), as well as National Institute of Health grants R01 GM085267 (to P.G. Wang) and R01 HD065122 (to X. Chen).

References

1. Dube DH, Bertozzi CR. *Nat Rev Drug Discov.* 2005; 4:477. [PubMed: 15931257]
2. Brockhausen, I.; Schachter, H.; Stanley, P. *Essentials of Glycobiology*. 2. Varki, A.; Cummings, RD.; Esko, JD.; Freeze, HH.; Stanley, P.; Bertozzi, CR.; Hart, GW.; Etzler, ME., editors. Vol. ch 9. Cold Spring Harbor; New York: 2009.
3. Storry JR, Olsson ML. *Immunohematology.* 2009; 25:48. [PubMed: 19927620]
4. Schnaar, RL.; Suzuki, A.; Stanley, P. *Essentials of Glycobiology*. 2. Varki, A.; Cummings, RD.; Esko, JD.; Freeze, HH.; Stanley, P.; Bertozzi, CR.; Hart, GW.; Etzler, ME., editors. Vol. ch 10. New York: 2009.
5. (a) Knirel YA, Perepelov AV, Kondakova AN, Senchenkova SN, Sidorczyk Z, Rozalski A, Kaca W. *Innate Immun.* 2011; 17:70. [PubMed: 20305038] (b) Wang Q, Perepelov AV, Feng L, Knirel YA, Li Y, Wang L. *FEMS Immunol Med Microbiol.* 2009; 55:47. [PubMed: 19040662] (c) Widmalm G, Leontein K. *Carbohydr Res.* 1993; 247:255. [PubMed: 7693348] (d) Liu B, Knirel YA, Feng L, Perepelov AV, Senchenkova SN, Wang Q, Reeves PR, Wang L. *FEMS Microbiol Rev.* 2008; 32:627. [PubMed: 18422615] (e) Knirel'Yu A, Kochetkov NK. *Biokhimiia.* 1994; 59:1784. [PubMed: 7533007]
6. Suzuki Y, Matsunaga M, Nagao Y, Taki T, Hirabayashi Y, Matsumoto M. *Vaccine.* 1985; 3:201. [PubMed: 4060848]
7. Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. *Neurology.* 1996; 47:237. [PubMed: 8710085]
8. (a) Schnaar RL. *FEBS Lett.* 2010; 584:1741. [PubMed: 19822144] (b) Kolter T, Proia RL, Sandhoff K. *J Biol Chem.* 2002; 277:25859. [PubMed: 12011101]
9. (a) Ernst B, Schwardt O, Mesch S, Wittwer M, Rossato G, Vedani A. *Chimia (Aarau).* 2010; 64:17. [PubMed: 21137678] (b) Ernst B, Magnani JL. *Nat Rev Drug Discov.* 2009; 8:661. [PubMed: 19629075]
10. Wilstermann M, Magnusson G. *Carbohydr Res.* 1995; 272:1. [PubMed: 7648584]

11. (a) Hedbys L, Johansson E, Mosbach K, Larsson PO. Carbohydr Res. 1989; 186:217. [PubMed: 2500235] (b) Vetere A, Miletich M, Bosco M, Paoletti S. Eur J Biochem. 2000; 267:942. [PubMed: 10672000] (c) Baisch G, Ohrlein R, Streiff M, Kolbinger F. Bioorg Med Chem Lett. 1998; 8:751. [PubMed: 9871535] (d) Su DM, Eguchi H, Yi W, Li L, Wang PG, Xia C. Org Lett. 2008; 10:1009. [PubMed: 18254640] (e) Wang Z, Gilbert M, Eguchi H, Yu H, Cheng J, Muthana S, Zhou L, Wang PG, Chen X, Huang X. Adv Synth Catal. 2008; 350:1717. [PubMed: 20305750]
12. Yu H, Thon V, Lau K, Cai L, Chen Y, Mu S, Li Y, Wang PG, Chen X. Chem Commun (Camb). 2010; 46:7507. [PubMed: 20830443]
13. Yan J, Chen X, Wang F, Cao H. Org Biomol Chem. 2013; 11:842. [PubMed: 23241945]
14. Li L, Liu Y, Wang W, Cheng J, Zhao W, Wang P. Carbohydr Res. 2012; 355:35. [PubMed: 22633137]
15. Li SP, Hsiao WC, Yu CC, Chien WT, Lin HJ, Huang LD, Lin CH, Wu WL, Wu SH, Lin CC. Adv Synth Catal. 2014; 356:3199.
16. Muthana MM, Qu J, Xue M, Klyuchnik T, Siu A, Li Y, Zhang L, Yu H, Li L, Wang PG, Chen X. Chem Commun (Camb). 2015; 51:4595. [PubMed: 25686901]
17. (a) Hayashi T, Murray BW, Wang R, Wong CH. Bioorg Med Chem. 1997; 5:497. [PubMed: 9113327] (b) Burkart MD, Vincent SP, Duffels A, Murray BW, Ley SV, Wong CH. Bioorg Med Chem. 2000; 8:1937. [PubMed: 11003139]
18. (a) Yu H, Chokhawala H, Karpel R, Yu H, Wu B, Zhang J, Zhang Y, Jia Q, Chen X. J Am Chem Soc. 2005; 127:17618. [PubMed: 16351087] (b) Sugiarto G, Lau K, Li Y, Khedri Z, Yu H, Le DT, Chen X. Mol Biosyst. 2011; 7:3021. [PubMed: 21858283] (c) Sugiarto G, Lau K, Qu J, Li Y, Lim S, Mu S, Ames JB, Fisher AJ, Chen X. ACS Chem Biol. 2012; 7:1232. [PubMed: 22583967]
19. Yu H, Yu H, Karpel R, Chen X. Bioorg Med Chem. 2004; 12:6427. [PubMed: 15556760]
20. Yu H, Huang S, Chokhawala H, Sun M, Zheng H, Chen X. Angew Chem Int Ed Engl. 2006; 45:3938. [PubMed: 16721893]
21. Meng X, Yao W, Cheng J, Zhang X, Jin L, Yu H, Chen X, Wang F, Cao H. J Am Chem Soc. 2014; 136:5205. [PubMed: 24649890]

Figure 1.

Galacto-*N*-biose (GNB) and natural glycans contain GNB or derivatives, and sialyl or di-sialyl GNB.

Scheme 1.

One-pot two-enzyme system for the synthesis of GNB and derivatives. BiGalK, galactokinase from *Bifidobacterium infantis* ATCC15697; BiGalHexNAcP, D-galactosyl- β 1-3-*N*-acetyl-D-hexosamine phosphorylase from *B. infantis* ATCC15697.

Scheme 2.

One-pot two-enzyme system for the synthesis of sialyl GNB and derivatives. NmCSS, CMP-Sia synthetase from *Neisseria meningitidis*; PmST1 E271F/R313Y, *Pasteurella multocida* α 2–3-sialyltransferase 1 mutant with decreased sialidase activity.

Scheme 3.

One-pot two-enzyme system for the synthesis of di-sialyl GNB derivatives. NmCSS, CMP-Sia synthetase from *Neisseria meningitidis*; Pd2,6ST, α 2–6-sialyltransferase from *Photobacterium damsela*.

Table 1

Synthesis of GNB and derivatives via the one-pot two-enzyme system shown in Scheme 1. ND, not detected.

Donors	Acceptors	Products	Yields (%)
Gal 1	GalNAc 11	Galβ1-3GalNAc (GNB) 12	95
Gal2deoxy 2		Gal2deoxyβ1-3GalNAc 13	80
GalNH ₂ 3		GalNH ₂ β1-3GalNAc 14	ND
GalN ₃ 4		GalN ₃ β1-3GalNAc 15	ND
GalF 5		GalFβ1-3GalNAc 16	28
Talose (Tal) 6		Talβ1-3GalNAc 17	ND

Donors	Acceptors	Products	Yields (%)
Gal6deoxy 7		Gal6deoxyβ1–3GalNAc 18	87
GalA 8		GalAβ1–3GalNAc 19	84
Gal6N ₃ 9		Gal6N ₃ β1–3GalNAc 20	76
Gal6F 10		Gal6Fβ1–3GalNAc 21	80 ¹³

Table 2

Synthesis of sialyl GNB and derivatives via the one-pot two-enzyme $\alpha 2$ –3-sialylation system shown in Scheme 2.

Acceptors	Products	Yields (%)
12	<p>Neu5Acα2–3Galβ1–3GalNAc</p> <p>22</p>	94
13	<p>Neu5Acα2–3Gal2deoxyβ1–3GalNAc</p> <p>23</p>	82
16	<p>Neu5Acα2–3-GalFβ1–3GalNAc</p> <p>24</p>	87
18	<p>Neu5Acα2–3Gal6deoxyβ1–3GalNAc</p> <p>25</p>	85
19	<p>Neu5Acα2–3GalAβ1–3GalNAc</p> <p>26</p>	16
20	<p>Neu5Acα2–3Gal6N₃β1–3GalNAc</p> <p>27</p>	79

Table 3

Synthesis of di-sialyl GNB derivatives via the one-pot two-enzyme α 2–6-sialylation system shown in Scheme 3.

Acceptors	Products	Yields (%)
25	<p>Neu5Acα2–3Gal6deoxyβ1–3-(Neu5Acα2–6)GalNAc</p> <p>28</p>	81
26	<p>Neu5Acα2–3GalAβ1–3-(Neu5Acα2–6)GalNAc</p> <p>29</p>	57
27	<p>Neu5Acα2–3Gal6N$_3$$\beta$1–3-(Neu5Ac$\alpha$2–6)GalNAc</p> <p>30</p>	75